TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of appropriateness of CTS management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Receiver Operating Characteristic Curve (ROC AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's reported anxiety symptoms immediately after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's reported depressive symptoms immediately after the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Upper extremity motor ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of daily living related to the upper extremity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Voluntary movement and mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving T-VASI 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving F-VASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence Risk of P. vivax relapse at month 6
Endpoint domain: Adverse events/effects
Primary endpoint: Change in University of California, Los Angeles (UCLA) Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lysholm Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxford Knee Score (OKS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Single Assessment Numeric Evaluation (SANE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMR grade ≤2+ (moderate or less)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cannabis use frequency from baseline through follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cannabis Use Disorder symptoms from baseline through follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in real-world stress-elicited cannabis use from baseline to post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Lower Extremity Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in pain quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of STP707
Endpoint domain: Adverse events/effects
Primary endpoint: Severe aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Pulmonary Function Tests (PFTs): Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in 12 -Lead Electrochardiograms (ECGs): Mean Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Miscarriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in cachexia staging score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the severity of nasal SAR symptoms as assessed by total nasal symptom score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the nasal obstruction using peak nasal inspiratory flow (PNIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the severity of nasal SAR symptoms as assessed by visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hand osteoarticular involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: The best deep response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of quality of life assessed with EPIC26
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change of quality of life assessed with EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Data Collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Rating on Ease of Use for the Mobile Application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drop Jump Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop Jump Contact Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop Jump Reactive Strength Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work and Social Adjustment Scale (WSAS) Change
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occurrence of Physeal dysplasia after treatment start
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rise of serum creatine phosphokinase levels AND concurrent musculoskeletal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rise in transaminase (ALT and AST) and concurrent rise in bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Cumulative incidence of ocular toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: IGRA status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall incidence of post COVID-19 condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of post COVID-19 condition beyond 2-3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term organ damage associated with post COVID-19 condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of time in target SpO2 range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Self-Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SpO2 readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: waist to hip ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Infectious/Antibiotic Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AEs Grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pupil size from low light under high-light conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F1 score for classification of cardiac contractility abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in radiologic liver parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS III) off medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug and alcohol-related overdose mortality
Endpoint domain: Mortality/survival
Primary endpoint: Satisfaction with outpatient service
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of consumers deciding not to have the procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Periodontal health assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sheldon Cohen Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of technical problems disturbing the colonoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Overall incidence of all IP-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall severity of all IP-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of epigenetic-mediated immune exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systolic Blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to Participate in Social Roles and Activities - PROMIS Short Form 8a
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ecological Momentary Assessment (EMA) app
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Number of chair lifts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in PCLS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in DASS-21 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in QSCPGS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in SSQ6 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in RSQ score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Kupperman Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLR-transformed Abundance of Any Significant Taxa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bowel habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of participants with at least one PGM1-CDG related event
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ventilation distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects who enroll
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Weight Control Strategies Scale (WCSS) Score for Social Contacts
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Angiographic recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic ICH at 27 ±3hrs post randomization
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Communication Participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Montgomery Burden Inventory (MBI)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Adherence to HMV treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of preterm infants receiving the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intra Ocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: functional prognosis at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication-Assisted Treatment (MAT) Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cut-off value for SVC-CI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Average of Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment Upper-Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth Differentiation Factor-15 (GDF-15) level in the plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth Differentiation Factor-15 (GDF-15) level in the cerebrospinal fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the percent change from Baseline in serum C-telopeptide of type 1 collagen (AUEC of %Cfb sCTX-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average change in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Glucose Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Positive Cells for CD30 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients experiencing dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Definition of maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Hemostatic evolution through transfusion event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Haematologic measures evolution through transfusion event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic accuracy of acute clinical diagnosis of concussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mean daily blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time from the start of ATI to meeting ART re-initiation criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who sustain post-treatment HIV control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who experience adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titre (GMT) of Binding antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change on Montgomery Åsberg Depression Rating Scale (MADRS-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Total Number of HAE Attacks to 3 Months on Lanadelumab Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of pro-inflammatory macrophages activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mitochondrial genome mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Unexpected Related Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Stinging
Endpoint domain: Adverse events/effects
Primary endpoint: Acute gastrointestinal illness (AGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ratio of metaphase-2 oocytes to total number of follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Areal Bone Mineral Density (BMD) at the Neck of Femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DNA sequencing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: RNA sequencing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mass Cytometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite of major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Length of stay exceeding 58 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Circulating PlexinD1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting toxicity (DLT) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Prenatal distress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximal pain in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extended Nordic Musculoskeletal Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maslach Burnout Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vocational Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain Coping Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: New or enlarged silent cerebral infarcts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective effective rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High glucose variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unawareness hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Menopause-Specific Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma sugammadex concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma sugammadex-rocuronium complex concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomy theoretical questions test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change from Baseline for Apolipoprotein B (ApoB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of spontaneous entry into labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fasting Insulin (I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycosylated Hemoglobin (HBA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Static Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of participants with addictive behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Return of Gastrointestinal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total dose/duration of remifentanil and norepinephrine during mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hughes-Hatsukami Withdrawal Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Smoking urges as assessed by the Tiffany-Drobes Questionnaire of Smoking Urges (QSU) Brief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in endometrial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at rest and motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Palsy Quality of Life Questionnaire for Children and Adolescent
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knowledge and practice of diabetic foot care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Screening for diabetic foot complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Scale for Suicidal Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of tele-therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms global assessment of relief (SGA) responder rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants with HIV-1 RNA ≥ 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neurologic outcome 3 months following ICU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ALBI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Sleep Onset Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety events (AE, SAE, UADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of EUROSCUP Fixe
Endpoint domain: Adverse events/effects
Primary endpoint: sNfL levels at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sNfL levels at Week 96
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Phosphatidylethanol (PEth) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quantity of drinks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak drinking quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP levels in blood at end of intervention period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes